ADAM17 and glomerulosclerosis: In CKD, the increase in Ang-II induces disintegrin and metalloproteinase-17 (ADAM17) expression, which activates the epidermal growth factor receptor/mitogen-activated protein kinase (EGFR-MAPK) pathway implicated in fibrosis, glomerulosclerosis, tubular dilation and atrophy [4].